shp77  (ATCC)

Journal: Cancer Biology & Medicine

Article Title: Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway

doi: 10.20892/j.issn.2095-3941.2024.0241

Figure Lengend Snippet: Chidamide inhibits malignancy proliferation in SCLC. (A-F) Effects of chidamide on the viability of various neuroendocrine SCLC cells in vitro (A-C), subcutaneous tumor growth, and toxicity in vivo (D-F). (G, H) Expression of Ki-67 in the control and chidamide groups. (I) Gene set enrichment analysis (GSEA) of apoptosis pathway transcriptomic differences in SCLC cells in the chidamide and control groups. (J) Quantification of apoptosis-associated gene expression in the chidamide and control groups according to qPCR and WB. (K-M) Flow cytometry analyses of SCLC cell apoptosis after treatment with various chidamide concentrations. Bars represent the mean ± SD values. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Student’s t -test (E, H, J), one-way ANOVA (M). These experiments were performed three times.

Article Snippet: Human SCLC cell lines (SHP77, NCI-H889, NCI-H446, and DMS53), the human mononuclear cell line, THP1, and the murine macrophage cell line, RAW264.7, were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA).

Techniques: In Vitro, In Vivo, Expressing, Control, Gene Expression, Flow Cytometry

Journal: Cancer Biology & Medicine

Article Title: Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway

doi: 10.20892/j.issn.2095-3941.2024.0241

Figure Lengend Snippet: Chidamide promotes CCL2 expression in SCLC. (A) Differential gene expression changes in SHP77 and H889 cells before and after treatment with chidamide. KEGG signaling pathway enrichment in human (B) and murine SCLC cells (D) before and after chidamide treatment. Differential cytokine heatmap in cytokine-cytokine receptor interaction signaling pathways in human (C) and murine SCLC cells (E). (F) Venn diagram of the above-mentioned differentially expressed cytokines in the three SCLC cell lines. (G) Expression of three cytokines based on RNA sequencing. (H) Expression of three cytokines in SCLC cells verified by qPCR. (I) CCL2 expression between normal and SCLC tissues in the GSE43346 (43/25), GSE60052 (7/79), GSE15240 (3/38), and GSE149507 (18/18) datasets. (J) Survival curve of 81 SCLC patients with high or low CCL2 expression. (K-M) Changes in CCL2 expression in SCLC cells treated with chidamide for various times according to qPCR (K), ELISA (L), and WB (M). Bars represent the mean ± SD values. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Student’s t -test (G, H, I), one-way ANOVA (K, L). These experiments were performed three times (H, K, L, M).

Article Snippet: Human SCLC cell lines (SHP77, NCI-H889, NCI-H446, and DMS53), the human mononuclear cell line, THP1, and the murine macrophage cell line, RAW264.7, were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA).

Techniques: Expressing, Gene Expression, Protein-Protein interactions, RNA Sequencing, Enzyme-linked Immunosorbent Assay